Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yasmin L. Jayasinghe, W. Hamish B. Wallace & Richard A. Anderson. (2018) Ovarian function, fertility and reproductive lifespan in cancer patients. Expert Review of Endocrinology & Metabolism 13:3, pages 125-136.
Read now
Read now
Katarzyna Pankiewicz, Grzegorz Szewczyk, Tomasz Mikołaj Maciejewski & Dariusz Szukiewicz. (2017) Strategies for overcoming oncological treatment-related ovarian dysfunction – literature review. Gynecological Endocrinology 33:11, pages 830-835.
Read now
Read now
Aysun Şikar Aktürk, Remzi Abalı, Mehmet Aytaç Yüksel, Eda Çelik Güzel, Savaş Güzel & Rebiay Kıran. (2014) The effects of isotretinoin on the ovarian reserve of females with acne. Gynecological Endocrinology 30:1, pages 30-33.
Read now
Read now
Articles from other publishers (82)
Sule Yildiz, Gamze Bildik, Can Benlioglu, Volkan Turan, Ece Dilege, Melis Ozel, Samuel Kim & Ozgur Oktem. (2023) Breast cancer treatment and ovarian function. Reproductive BioMedicine Online 46:2, pages 313-331.
Crossref
Crossref
Kathryn J Ruddy, Daniel J Schaid, Anthony Batzler, Reena S Cecchini, Ann H Partridge, Aaron Norman, Louis Fehrenbacher, Elizabeth A Stewart, Emanuel Trabuco, Elizabeth Ginsburg, Fergus J Couch, Peter A Fasching, Celine Vachon & Patricia A Ganz. (2021) Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. JNCI: Journal of the National Cancer Institute 113:8, pages 1105-1108.
Crossref
Crossref
Seongmin Kim, Sung-Woo Kim, Soo-Jin Han, Sanghoon Lee, Hyun-Tae Park, Jae-Yun Song & Tak Kim. (2021) Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. International Journal of Molecular Sciences 22:14, pages 7484.
Crossref
Crossref
Hilary Laura Martin, Shahid Ullah, Nazim Abbas, Alex Scott‐Hoy, Ganessan Kichenadasse, Christos Stelios Karapetis, Amitesh Roy, Shawgi Sukumaran, David M Ross, Muhammad Adnan Khattak & Bogda Koczwara. (2021) Predicting chemotherapy‐induced menopause using baseline and post‐chemotherapy anti‐Müllerian hormone levels: Results of a pilot study. Cancer Reports 4:3.
Crossref
Crossref
Charlotte Sonigo, Michaël Grynberg, Sophie Bringer & Nathalie Sermondade. (2019) Oncofertilité et cancer du sein. Bulletin du Cancer 106:12, pages S43-S52.
Crossref
Crossref
M. E. (Elena) ter Welle-Butalid, I. J. H. (Ingeborg) Vriens, J. G. (Josien) Derhaag, E. M. (Edward) Leter, C. E. (Christine) de Die-Smulders, M. (Marjolein) Smidt, R. J. T. (Ron) van Golde & V. C. G. (Vivianne) Tjan-Heijnen. (2019) Counseling young women with early breast cancer on fertility preservation. Journal of Assisted Reproduction and Genetics 36:12, pages 2593-2604.
Crossref
Crossref
K.E. Palinska-Rudzka, T. Ghobara, N. Parsons, J. Milner, G. Lockwood & G.M. Hartshorne. (2019) Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer. Reproductive BioMedicine Online 39:4, pages 712-720.
Crossref
Crossref
Darcie D Seachrist & Ruth A Keri. (2019) The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer. Endocrinology 160:5, pages 1097-1110.
Crossref
Crossref
Giuliano M. Bedoschi, Paula A. Navarro & Kutluk H. Oktay. (2019) Novel insights into the pathophysiology of chemotherapy-induced damage to the ovary. Panminerva Medica 61:1.
Crossref
Crossref
Corrine Welt & Alan Schneyer. 2019. The Ovary. The Ovary
95
105
.
Yasmin Gosiengfiao & Veronica Gomez-Lobo. 2019. Textbook of Oncofertility Research and Practice. Textbook of Oncofertility Research and Practice
145
151
.
Dong-Yun Lee, Yeon Hee Park, Jeong Eon Lee & DooSeok Choi. (2018) Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy. Breast Cancer Research and Treatment 171:3, pages 649-656.
Crossref
Crossref
Hyun-Ah Kim, Jihye Choi, Chan Sub Park, Min-Ki Seong, Sung-Eun Hong, Jae-Sung Kim, In-Chul Park, Jin Kyung Lee, Woo Chul Noh & _ _. (2018) Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery. Endocrine Connections 7:8, pages 949-956.
Crossref
Crossref
Katlynn M. Mathis, Kathleen M. Sturgeon, Renate M. Winkels, Joachim Wiskemann, Nancy I. Williams & Kathryn Schmitz. (2018) Exercise and chemotherapy-induced amenorrhea. Medical Hypotheses 116, pages 49-53.
Crossref
Crossref
Christine Decanter, Marc Cloquet, Audrey Dassonneville, Emmanuelle D'Orazio, Audrey Mailliez & Pascal Pigny. (2018) Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy. Reproductive BioMedicine Online 36:6, pages 711-718.
Crossref
Crossref
Emina Malisic, Snezana Susnjar, Jelena Milovanovic, Natasa Todorovic-Rakovic & Vesna Kesic. (2017) Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia. Archives of Gynecology and Obstetrics 297:2, pages 495-503.
Crossref
Crossref
Antonia Wenners, Jana Grambach, Juliane Koss, Nicolai Maass, Walter Jonat, Andreas Schmutzler & Christoph Mundhenke. (2017) Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. BMC Cancer 17:1.
Crossref
Crossref
Anne Perdrix, Mathilde Saint-Ghislain, Marie Degremont, Marion David, Zena Khaznadar, Agnès Loeb, Marianne Leheurteur, Frédéric Di Fiore & Florian Clatot. (2017) Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer. Reproductive BioMedicine Online 35:4, pages 468-474.
Crossref
Crossref
Elisabeth Trapp, J. Steidl, B. Rack, M.S. Kupka, U. Andergassen, J. Jückstock, A. Kurt, T. Vilsmaier, A. de Gregorio, N. de Gregorio, M. Tzschaschel, C. Lato, A. Polasik, H. Tesch, A. Schneeweiss, M.W. Beckmann, P.A. Fasching, W. Janni & V. Müller. (2017) Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy – A translational research project of the SUCCESS A study. The Breast 35, pages 130-135.
Crossref
Crossref
Erica B. Mahany & John F. RandolphJr.Jr.. (2017) Biochemical and Imaging Diagnostics in Endocrinology. Endocrinology and Metabolism Clinics of North America 46:3, pages 679-689.
Crossref
Crossref
A. Dezellus, P. Barriere, M. Campone, C. Lemanski, L. Vanlemmens, L. Mignot, T. Delozier, C. Levy, C. Bendavid, M. Debled, T. Bachelot, C. Jouannaud, C. Loustalot, M.A. Mouret-Reynier, A. Gallais-Umbert, D. Masson & T. Freour. (2017) Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. European Journal of Cancer 79, pages 72-80.
Crossref
Crossref
Michael V. Homer, Lindsey M. Charo, Loki Natarajan, Carolyn Haunschild, Karine Chung, Jun J. Mao, Angela M. DeMicheleH. Irene Su. (2017) Genetic variants of age at menopause are not related to timing of ovarian failure in breast cancer survivors. Menopause 24:6, pages 663-668.
Crossref
Crossref
T. Fréour, P. Barrière & D. Masson. (2017) Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. European Journal of Cancer 74, pages 1-8.
Crossref
Crossref
Yasmin Gosiengfiao & Veronica Gomez-Lobo. 2017. Pediatric and Adolescent Oncofertility. Pediatric and Adolescent Oncofertility
31
38
.
Giuliano Bedoschi, Paula Andrea Navarro & Kutluk Oktay. (2016) Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncology 12:20, pages 2333-2344.
Crossref
Crossref
Dalia O. Saleh & Dina F. Mansour. (2016) Ovario-protective effects of genistein against cyclophosphamide toxicity in rats: Role of anti-müllerian hormone and oestradiol. European Journal of Pharmacology 789, pages 163-171.
Crossref
Crossref
Akira Iwase, Tomoko Nakamura, Satoko Osuka, Sachiko Takikawa, Maki Goto & Fumitaka Kikkawa. (2015) Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?. Reproductive Medicine and Biology 15:3, pages 127-136.
Crossref
Crossref
Lea K. KrekowBeth A. HellerstedtRufus P. ColleaSteven PapishShrinivas M. DiggikarRegina RestaSvetislava J. VukeljaFrankie Ann HolmesPraveen K. ReddyLina AsmarYunfei WangPatricia S. FoxSusan R. PeckJoyce O’Shaughnessy. (2016) Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole. Journal of Clinical Oncology 34:14, pages 1594-1600.
Crossref
Crossref
Anne-Sophie Hamy, Raphaël Porcher, Sarah Eskenazi, Caroline Cuvier, Sylvie Giacchetti, Florence Coussy, Hamid Hocini, Bertrand Tournant, Francine Perret, Sylvie Bonfils, Patrick Charvériat, Jean-Marc Lacorte & Marc Espie. (2016) Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies. Reproductive BioMedicine Online 32:3, pages 299-307.
Crossref
Crossref
Cong Xue, Roujun Peng, Ye Cao, Shusen Wang, Yanxia Shi, Xin An, Fei Xu & Zhongyu Yuan. (2016) Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. PLOS ONE 11:2, pages e0148849.
Crossref
Crossref
Ângela Marcon D’Avila, Vanderlei Biolchi, Edison Capp & Helena von Eye Corleta. (2015) Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide. Journal of Ovarian Research 8:1.
Crossref
Crossref
Agnese Barnabei, Lidia Strigari, Paolo Marchetti, Valentina Sini, Liana De Vecchis, Salvatore Maria Corsello & Francesco Torino. (2015) Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram. The Oncologist 20:10, pages 1111-1118.
Crossref
Crossref
Kathryn J. Ruddy, Hao Guo, William Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth A. Overmoyer, Clifford Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer, Ann H. Partridge & Sara M. Tolaney. (2015) Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial). Breast Cancer Research and Treatment 151:3, pages 589-596.
Crossref
Crossref
Akira Iwase, Tomoko Nakamura, Tatsuo Nakahara, Maki Goto & Fumitaka Kikkawa. (2015) Anti-Müllerian Hormone and Assessment of Ovarian Reserve After Ovarian Toxic Treatment: A Systematic Narrative Review. Reproductive Sciences 22:5, pages 519-526.
Crossref
Crossref
Noa Hasky, Shiri Uri-Belapolsky, Keren Goldberg, Irit Miller, Hadas Grossman, Salomon M. Stemmer, Irit Ben-Aharon & Ruth Shalgi. (2015) Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?. Human Reproduction 30:5, pages 1089-1101.
Crossref
Crossref
Cheryl E. Dunlop & Richard A. Anderson. (2015) Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. Maturitas 80:3, pages 245-250.
Crossref
Crossref
Yuki HIMOTO, Aki KIDO, Koji FUJIMOTO, Sayaka DAIDO, Kayo KIGUCHI, Fuki SHITANO, Tsukasa BABA, Noriomi MATSUMURA, Ikuo KONISHI & Kaori TOGASHI. (2015) MR Imaging-based Evaluation of Morphological Changes in the Uterus and Ovaries of Patients Following Neoadjuvant Chemotherapy for Cervical Cancer. Magnetic Resonance in Medical Sciences 14:1, pages 65-72.
Crossref
Crossref
Richard A. Anderson. 2015. Cancer Treatment and the Ovary. Cancer Treatment and the Ovary
35
45
.
Hui-Chun Irene Su, Carolyn Haunschild, Karine Chung, Sara Komrokian, Sarah Boles, Mary Dupuis Sammel & Angela DeMichele. (2014) Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer 120:23, pages 3691-3698.
Crossref
Crossref
Anne-Sophie Hamy, Raphaël Porcher, Caroline Cuvier, Sylvie Giacchetti, Marie-Hélène Schlageter, Christiane Coussieu, Héloise Gronier, Jean-Paul Feugeas, Nadir Adoui, Jean-Marc Lacorte, Catherine Poirot, Mohamed Habdous & Marc Espié. (2014) Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone. Reproductive BioMedicine Online 29:5, pages 573-580.
Crossref
Crossref
Yogeshwar MakanjiJie ZhuRama MishraChris HolmquistWinifred P. S. WongNeena B. Schwartz, Kelly E. Mayo & Teresa K. Woodruff. (2014) Inhibin at 90: From Discovery to Clinical Application, a Historical Review. Endocrine Reviews 35:5, pages 747-794.
Crossref
Crossref
V. Tiong, A. M. Rozita, N. A. Taib, C. H. Yip & C. H. Ng. (2014) Incidence of Chemotherapy-Induced Ovarian Failure in Premenopausal Women Undergoing Chemotherapy for Breast Cancer. World Journal of Surgery 38:9, pages 2288-2296.
Crossref
Crossref
Hady El Hachem, David Atallah & Michael Grynberg. (2014) Fertility preservation in breast cancer patients. Future Oncology 10:10, pages 1767-1777.
Crossref
Crossref
Jianli Zhao, Jieqiong Liu, Kai Chen, Shunrong Li, Ying Wang, Yaping Yang, Heran Deng, Weijuan Jia, Nanyan Rao, Qiang Liu & Fengxi Su. (2014) What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Research and Treatment 145:1, pages 113-128.
Crossref
Crossref
Kathryn J. Ruddy, Anne O’Neill, Kathy D. Miller, Bryan P. Schneider, Emily Baker, Joseph A. Sparano, Chau Dang, Donald W. Northfelt, George W. SledgeJr.Jr. & Ann H. Partridge. (2014) Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Research and Treatment 144:3, pages 591-597.
Crossref
Crossref
Claudia Bozza, Fabio Puglisi, Matteo Lambertini, Etin-Osa Osa, Massimo Manno & Lucia Del Mastro. (2014) Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients. Endocrine-Related Cancer 21:1, pages R51-R65.
Crossref
Crossref
N. Lynn Henry, Rong Xia, Anne F. Schott, Daniel McConnell, Mousumi Banerjee & Daniel F. Hayes. (2014) Prediction of Postchemotherapy Ovarian Function Using Markers of Ovarian Reserve. The Oncologist 19:1, pages 68-74.
Crossref
Crossref
Maëliss Peigné & Christine Decanter. (2014) Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reproductive Biology and Endocrinology 12:1, pages 26.
Crossref
Crossref
Francesco Torino, Agnese Barnabei, Liana De Vecchis, Valentina Sini, Francesco Schittulli, Paolo Marchetti & Salvatore Maria Corsello. (2014) Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Critical Reviews in Oncology/Hematology 89:1, pages 27-42.
Crossref
Crossref
Richard A. Anderson, Mikkel Rosendahl, Thomas W. Kelsey & David A. Cameron. (2013) Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. European Journal of Cancer 49:16, pages 3404-3411.
Crossref
Crossref
N.H. Turner, A. Partridge, G. Sanna, A. Di Leo & L. Biganzoli. (2013) Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Annals of Oncology 24:9, pages 2224-2235.
Crossref
Crossref
Remzi Abali, Mehmet Aytac Yuksel, Cevat Aktas, Cem Celik, Savas Guzel, Gamze Erfan & Onder Sahin. (2013) Decreased ovarian reserve in female Sprague–Dawley rats induced by isotretinoin (retinoic acid) exposure. Reproductive BioMedicine Online 27:2, pages 184-191.
Crossref
Crossref
Atsuko Sugita, Akira Iwase, Maki Goto, Tatsuo Nakahara, Tomoko Nakamura, Mika Kondo, Satoko Osuka, Masahiko Mori, Ai Saito & Fumitaka Kikkawa. (2013) One-year follow-up of serum antimüllerian hormone levels in patients with cystectomy: are different sequential changes due to different mechanisms causing damage to the ovarian reserve?. Fertility and Sterility 100:2, pages 516-522.e3.
Crossref
Crossref
Richard A. Anderson & W. Hamish B. Wallace. (2013) Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertility and Sterility 99:6, pages 1469-1475.
Crossref
Crossref
Helena Mörse, Maria Elfving, Anna Lindgren, Pål Wölner‐Hanssen, Claus Yding Andersen & Ingrid Øra. (2012) Acute onset of ovarian dysfunction in young females after start of cancer treatment. Pediatric Blood & Cancer 60:4, pages 676-681.
Crossref
Crossref
Jennifer E. Mersereau & Jennifer T. Sandbulte. (2013) Fertility Preservation in Young Women with Breast Cancer. Current Obstetrics and Gynecology Reports 2:1, pages 59-64.
Crossref
Crossref
Katherine E. Dillon, Mary D. Sammel, Maureen Prewitt, Jill P. Ginsberg, Dana Walker, Jennifer E. Mersereau, Yasmin Gosiengfiao & Clarisa R. Gracia. (2013) Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertility and Sterility 99:2, pages 477-483.e1.
Crossref
Crossref
P. Hadji, M. Gnant, J.J. Body, N.J. Bundred, A. Brufsky, R.E. Coleman, T.A. Guise, A. Lipton & M.S. Aapro. (2012) Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?. Cancer Treatment Reviews 38:6, pages 798-806.
Crossref
Crossref
S. Morgan, R.A. Anderson, C. Gourley, W.H. Wallace & N. Spears. (2012) How do chemotherapeutic agents damage the ovary?. Human Reproduction Update 18:5, pages 525-535.
Crossref
Crossref
David M. Robertson. (2012) Inhibins and activins in blood: Predictors of female reproductive health?. Molecular and Cellular Endocrinology 359:1-2, pages 78-84.
Crossref
Crossref
Jenny A. Visser, Izaäk Schipper, Joop S. E. Laven & Axel P. N. Themmen. (2012) Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nature Reviews Endocrinology 8:6, pages 331-341.
Crossref
Crossref
Megan E. B. Clowse, Lindsey Harward, Lisa Criscione‐Schreiber, David Pisetsky & Susannah Copland. (2012) Anti‐Müllerian hormone: A better marker of ovarian damage from cyclophosphamide. Arthritis & Rheumatism 64:5, pages 1305-1310.
Crossref
Crossref
Francesco Torino, Agnese Barnabei, Liana De Vecchis, Marialuisa Appetecchia, Lidia Strigari & Salvatore M Corsello. (2012) Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. Endocrine-Related Cancer 19:2, pages R21-R33.
Crossref
Crossref
R.A. Anderson, S.M. Nelson & W.H.B. Wallace. (2012) Measuring anti-Müllerian hormone for the assessment of ovarian reserve: When and for whom is it indicated?. Maturitas 71:1, pages 28-33.
Crossref
Crossref
Kathryn J. Ruddy & Ann H. Partridge. 2012. Reproductive Health and Cancer in Adolescents and Young Adults. Reproductive Health and Cancer in Adolescents and Young Adults
77
87
.
Richard A Anderson. (2011) Can Ovarian Reserve Assessment Predict Fertility following Breast Cancer Treatment?. Women's Health 7:6, pages 623-625.
Crossref
Crossref
Audrey Mailliez, Christine Decanter & Jacques Bonneterre. (2011) Chimiothérapie adjuvante de cancer du sein et fertilité : estimation de l’impact, options de préservation et place de l’oncologue. Bulletin du Cancer 98:7, pages 741-751.
Crossref
Crossref
Bernd GerberGunter von MinckwitzHeinrich StehleToralf ReimerRicardo FelberbaumNikolai MaassDorothea FischerHarald L. SommerBettina ConradOlaf OrtmannTanja FehmMahdi RezaiKeyur MehtaSibylle Loibl. (2011) Effect of Luteinizing Hormone–Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study. Journal of Clinical Oncology 29:17, pages 2334-2341.
Crossref
Crossref
Melissa C Hulvat & Jacqueline S Jeruss. (2011) Fertility preservation options for young women with breast cancer. Current Opinion in Obstetrics & Gynecology 23:3, pages 174-182.
Crossref
Crossref
W. Hirokawa, A. Iwase, M. Goto, S. Takikawa, Y. Nagatomo, T. Nakahara, B. Bayasula, T. Nakamura, S. Manabe & F. Kikkawa. (2011) The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. Human Reproduction 26:4, pages 904-910.
Crossref
Crossref
H. Irene Su, Karine Chung, Mary D. Sammel, Clarisa R. Gracia & Angela DeMichele. (2011) Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors. Fertility and Sterility 95:5, pages 1857-1859.
Crossref
Crossref
Joseph M. Letourneau, Michelle E. Melisko, Marcelle I. Cedars & Mitchell P. Rosen. (2010) A changing perspective: improving access to fertility preservation. Nature Reviews Clinical Oncology 8:1, pages 56-60.
Crossref
Crossref
P. Fénichel & N. Chevalier. (2011) Existe-t-il des médicaments fertiloprotecteurs en cas de chimiothérapie chez la femme ?. Gynécologie Obstétrique & Fertilité 39:1, pages 63-66.
Crossref
Crossref
Mikkel Rosendahl, Claus Yding Andersen, Nina la Cour Freiesleben, Anders Juul, Kristine Løssl & Anders Nyboe Andersen. (2010) Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertility and Sterility 94:1, pages 156-166.
Crossref
Crossref
Nathalie Chabbert-Buffet, Catherine Uzan, Joseph Gligorov, Suzette Delaloge, Roman Rouzier & Serge Uzan. (2010) Pregnancy after breast cancer: A need for global patient care, starting before adjuvant therapy. Surgical Oncology 19:1, pages e47-e55.
Crossref
Crossref
B. Gerber & M. Dieterich. (2009) Ovarielle Protektion unter Chemotherapie durch GnRH-AgonistenOvarian protection under chemotherapy by GnRH agonists. Gynäkologische Endokrinologie 8:1, pages 41-46.
Crossref
Crossref
H. Irene Su, Mary D. Sammel, Jamie Green, Luke Velders, Corrie Stankiewicz, Jennifer Matro, Ellen W. Freeman, Clarisa R. Gracia & Angela DeMichele. (2009) Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors. Cancer 116:3, pages 592-599.
Crossref
Crossref
Bo Yu, Nataki Douglas, Michel J. Ferin, Gary S. Nakhuda, Katherine Crew, Rogerio A. Lobo & Dawn L. Hershman. (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer, pages NA-NA.
Crossref
Crossref
John Yeh, Beom Su Kim, Yuan Jing Liang & Jennifer Peresie. (2009) Gonadotropin stimulation as a challenge to calibrate cisplatin induced ovarian damage in the female rat. Reproductive Toxicology 28:4, pages 556-562.
Crossref
Crossref
Mikkel Rosendahl, Johan Ahlgren, Jørn Andersen, Jonas Bergh, Carl Blomquist, Elisabet Lidbrink, Henrik Lindman, Henning Mouridsen, Karsten Bjerre & Michael Andersson. (2009) The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study. European Journal of Cancer 45:18, pages 3198-3204.
Crossref
Crossref
Melissa C. Hulvat & Jacqueline S. Jeruss. (2010) Maintaining Fertility in Young Women with Breast Cancer. Current Treatment Options in Oncology 10:5-6, pages 308-317.
Crossref
Crossref
M. Rosendahl, C. Y. Andersen, E. Ernst, L. G. Westergaard, P. E. Rasmussen, A. Loft & A. N. Andersen. (2008) Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Human Reproduction 23:11, pages 2475-2483.
Crossref
Crossref